Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.59 |
| ▸ | CNR2 | P34972 | 10/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612523 | 0.97 | CNR1 (0.57) | CNR1CNR2PPARA | |
| SCHEMBL4611371 | 0.93 | CNR1 (0.51) | CNR1CNR2PPARA | |
| SCHEMBL4612373 | 0.91 | CNR2 (0.52) | CNR1CNR2PPARA | |
| SCHEMBL3816975 | 0.91 | CNR2 (0.58) | CNR1CNR2 | |
| SCHEMBL4611618 | 0.91 | PDE4B (0.47) | CNR1CNR2 | |
| SCHEMBL4829939 | 0.89 | CNR2 (0.50) | CNR1CNR2 | |
| SCHEMBL14164187 | 0.89 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL4791922 | 0.89 | KDM4E (0.57) | CNR1CNR2PPARA | |
| SCHEMBL13814761 | 0.87 | CNR2 (0.63) | CNR1CNR2PPARA | |
| SCHEMBL923180 | 0.87 | CNR2 (0.71) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090149463-A1 | Therapeutic agents | CHENG LEIFENG | 2009-06-11 | — | — | US | disclosed |
| US-20090149463-A1 | Therapeutic agents | CHENG LEIFENG | 2009-06-11 | — | — | US | disclosed |
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1910304-A2 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1831177-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007020388-A1 | PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006067443-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149463-A1 | Therapeutic agents | NLN, BDNF, GAP43 | CNR1 173/4885CNR2 209/4885PPARA 504/4885 |
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | CNR1, CNR2, HTR3C | CNR1 1/4885CNR2 2/4885PPARA 827/4885 |
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | CNR1 597/4885CNR2 480/4885PPARA 509/4885 |
| US-20090156616-A1 | THERAPEUTIC AGENTS | NLN, BDNF, GAP43 | CNR1 173/4885CNR2 209/4885PPARA 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.